Breast cancer (BC) after curative chemotherapy (CT) in non-hodgkin's lymphoma (NHL): drug resistance as the major cause of treatment failure

Breast cancer after curative chemotherapy in non-Hodgkin's lymphoma: Examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer

Oncology Reports ◽

10.3892/or.11.4.899 ◽

2004 ◽

Author(s):

N. Tsavaris ◽

C. Kosmas ◽

H. Zorzos ◽

A. Lazaris ◽

M. Vadiaka ◽

...

Keyword(s):

Breast Cancer ◽

Drug Resistance ◽

Hodgkin’S Lymphoma ◽

De Novo ◽

Hodgkin's Lymphoma ◽

Retrospective Comparison ◽

HSR21-073: Febrile Neutropenia Outcomes Among Patients With Breast Cancer and Non-Hodgkin’s Lymphoma Receiving Pegfilgrastim Prophylaxis: A Real-World Analysis of Commercial and Medicare Claims From 2017-2018

Journal of the National Comprehensive Cancer Network ◽

10.6004/jnccn.2020.7718 ◽

2021 ◽

Vol 19 (3.5) ◽

pp. HSR21-073

Author(s):

Weijia Wang ◽

Edward Li ◽

Kim Campbell ◽

Ali McBride

Keyword(s):

Breast Cancer ◽

Febrile Neutropenia ◽

Real World ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Medicare Claims ◽

A model to predict delivery of reduced chemotherapy dose intensity in the first three cycles of treatment among patients with non-Hodgkin's lymphoma and breast cancer

10.1200/jco.2004.22.90140.6100 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 6100-6100

Author(s):

V. Caggiano ◽

V. A. Morrison ◽

M. Fridman ◽

D. J. Delgado

Keyword(s):

Breast Cancer ◽

Hodgkin’S Lymphoma ◽

Dose Intensity ◽

Hodgkin's Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Chemotherapy Dose ◽

Chemotherapy Dose Intensity

CXCL12 rs1801157 polymorphism in patients with breast cancer, hodgkin's lymphoma, and non-hodgkin's lymphoma

Journal of Clinical Laboratory Analysis ◽

10.1002/jcla.20346 ◽

2009 ◽

Vol 23 (6) ◽

pp. 387-393 ◽

Cited By ~ 28

Author(s):

Karen BrajÃ£o de Oliveira ◽

Julie Massayo Maeda Oda ◽

Julio Cesar Voltarelli ◽

Thiago Franco Nasser ◽

Mario Augusto Ono ◽

...

Keyword(s):

Breast Cancer ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

A model to predict delivery of reduced chemotherapy dose intensity in the first three cycles of treatment among patients with non-Hodgkin's lymphoma and breast cancer

10.1200/jco.2004.22.14_suppl.6100 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 6100-6100

Author(s):

V. Caggiano ◽

V. A. Morrison ◽

M. Fridman ◽

D. J. Delgado

Keyword(s):

Breast Cancer ◽

Hodgkin’S Lymphoma ◽

Dose Intensity ◽

Hodgkin's Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Chemotherapy Dose ◽

Chemotherapy Dose Intensity

Non-Hodgkin's lymphoma in women with breast cancer: A retrospective study of 46 patients

10.1200/jco.2004.22.14_suppl.6670 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 6670-6670 ◽

Cited By ~ 2

Author(s):

M. Roussel

Keyword(s):

Breast Cancer ◽

Retrospective Study ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Non-Hodgkin's lymphoma in women with breast cancer: A retrospective study of 46 patients

10.1200/jco.2004.22.90140.6670 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 6670-6670

Author(s):

M. Roussel

Keyword(s):

Breast Cancer ◽

Retrospective Study ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin’s lymphoma

Bone Marrow Transplantation ◽

10.1038/sj.bmt.1700783 ◽

1997 ◽

Vol 19 (10) ◽

pp. 983-988 ◽

Cited By ~ 3

Author(s):

A Fontelonga ◽

AJ Kelly ◽

FR MacKintosh ◽

S Hall ◽

P Monroe ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hodgkin’S Lymphoma ◽

Metastatic Breast ◽

High Dose Chemotherapy ◽

Hodgkin's Lymphoma ◽

High Dose ◽

Non Hodgkin's Lymphoma ◽

Chemotherapy Protocol

Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin’s lymphoma

Supportive Care in Cancer ◽

10.1007/s00520-014-2184-5 ◽

2014 ◽

Vol 22 (8) ◽

pp. 2167-2175 ◽

Cited By ~ 10

Author(s):

Wendy J. Langeberg ◽

Conchitina C. Siozon ◽

John H. Page ◽

P. K. Morrow ◽

Victoria M. Chia

Keyword(s):

Breast Cancer ◽

Hodgkin’S Lymphoma ◽

Primary Prophylaxis ◽

Hodgkin's Lymphoma ◽

Chemotherapy Cycle ◽

Risk Of Infection ◽

Overexpression of TRIP6 promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR) via regulating nuclear p27Kip1 expression in non-Hodgkin’s lymphoma

Tumor Biology ◽

10.1007/s13277-015-3939-4 ◽

2015 ◽

Vol 37 (1) ◽

pp. 1369-1378 ◽

Cited By ~ 14

Author(s):

Xiaobing Miao ◽

Xiaohong Xu ◽

Yaxun Wu ◽

Xinghua Zhu ◽

Xudong Chen ◽

...

Keyword(s):

Drug Resistance ◽

Cell Adhesion ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Tumor Proliferation ◽

P27kip1 Expression ◽